The European equity rebound continues and within the region the small cap stocks have been quietly performing very well. The WisdomTree Europe Small Cap Dividend ETF (NYSE: DFE) focuses on small cap stocks that pay high dividends.
The index that the ETF tracks is composed of the bottom 25 percent of stocks based on market capitalization in the WisdomTree Europe Dividend Index. The companies are then weighted based on annual cash dividend paid. The current yield on the ETF is 2.6 percent.
The ETF is heavily weighted in the U.K., Sweden, Italy, and Germany, with the four countries making up over 60 percent of the allocation. The four top sectors are the industrials, consumer discretionary, financials, and information technology. The ETF is fairly diversified with the top ten making up only 18 percent of the portfolio.
Top 10 Companies To Invest In Right Now: Drinks Americas Holdings Ltd (DKAM)
Drinks Americas Holdings, Ltd., incorporated in February 14, 2005, develops, produces, markets and/or distributes alcoholic and non-alcoholic beverages for sale primarily in the continental United States. Through its majority-owned subsidiaries, Drinks imports, distributes and markets premium wine and spirits and alcoholic beverages to beverage wholesalers throughout the United States and internationally. The alcoholic products distributed by the Company are KAH Tequila, Old Whiskey River Bourbon (R), Rheingold Beer, Damiana, a Mexican liqueur, Mexicali Beer, Agave 99, Chili Devil Beer, Crazy PigAle and Red Pig Ale. In June, 2011 the Company acquired the rights to distribute and market existing brands and products from Fabrica De Tequilas Finos S.A. de C.V. (Finos) and Cervecera Mexicana, S. de R.L. de C.V. (Cerveceria). In June 2011, the Company acquired the rights to distribute and market existing brands and products through a licensing agreement with Worldwide Beverage Imports, LLC, (WBI). On November 2, 2011, the Company acquired worldwide licensing and distribution rights on both the spirits and beer products owned or licensed by WBI. In June 2013, the Company announced the development of Drinks Americas Consumer Beverage Consulting Division.
The Company owns, distributes or licenses or collects royalties from a number of Spirits Brands to include Old Whiskey River Bourbon, Damiana Liqueur and Rheingold Beer. The Company owns 25% interest in Old Whiskey River Distilling Company, LLC which owns or licenses the related trademarks and trade names associated with the Old Whiskey River products.
The Company compets with Diageo, Allied Domecq, Pernod Ricard, Brown-Forman and Bacardi & Company, Ltd.
Advisors' Opinion:- [By Bryan Murphy]
Even though you're reading this now, odds are that three weeks ago you'd never even heard of Drinks Americas Holdings, Ltd. (OTCMKTS:DKAM). And, like so many other young, nano-cap stocks, it would be easy to assume the current strength being exhibited by DKAM is nothing but a short-term phenomenon, meaning there's no particular reason to jump on the stock now. If there was ever a reason to jump onto a micro cap name for a quick trade though, this may be it.
Best High Dividend Stocks For 2014: Actavis Inc (ACT)
Actavis, Inc., formerly Watson Pharmaceuticals, Inc., incorporated on February 1, 1985, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.
Actavis Pharma Segment
Actavis Pharma Segment is engaged in the development, manufacturing and sale of generic, branded generic and OTC pharmaceutical products. The Company�� portfolio of generic products includes products it has developed internally and products licensed from and distributed for third parties. The Company sells its generic prescription products primarily under the Watson Laboratories, Watson Pharma and Actavis Pharma labels, and its over-the-counter generic products under private label.
Actavis Specialty Brands Segment
The Company markets a number of branded products to physicians, hospitals, and other markets that it serves. The Company classifies these trademarked products as its brand pharmaceutical products. In April 2012, it launched Gelnique 3% (oxybutynin), a clear, odorless topical gel. Gelnique 3% was obtained through an exclusive licensing agreement with Antares. The Company�� promoted products are Rapaflo, Gelnique, Trelstar, Androderm, Generess Fe and Crinone. The Company�� Actavis Specialty Brands segment also receives other revenues consisting of co-promotion revenue and royaltie! s.
Anda Distribution Segment
The Company Anda Distribution business primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables and over-the-counter medicines to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains and physicians��offices. In addition, it sells to members of buying groups, which are independent pharmacies that join together to enhance their buying power. As of December 31, 2012, the Company distributes products from its facilities in Weston, Florida, Groveport, Ohio, and Olive Branch, Mississippi, as well as a small volume of product from Puerto Rico.
The Company competes with Teva Pharmaceutical Industries, Ltd., Mylan Inc., Sandoz, Inc, McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc.,
Advisors' Opinion:- [By Ben Levisohn]
Yesterday, shares of Actavis (ACT) gained 1.7% after it said it would pay $66 billion to buy Allergan (AGN). With another day to mull the news, shares have pushed shares of Actavis up more than 8%.
Associated Press Actavis CEO Brenton Saunders, left, and Allergan CEO David PyottWhat’s changed? Yesterday, investors seemed excited by the deal but worried about the price paid, one which forced Valeant’s (VRX) CEO to bow out of the race, while noting that “Valeant cannot justify to its own shareholders paying a price of $219 or more per share for Allergan.”
Today, those worries are nowhere to be found. This note from UBS analyst Marc Goodman is typical of sentiment around Actavis now:
We like�Actavis even more now. The Allergan deal should accelerate both top line and earnings growth and thus boost the P/E multiple of Actavis. We understand that there are many moving parts regarding the stock in the near term, with an equity raise, convert, and arb positioning; however, looking through the noise, we see a very attractive company, trading at a very attractive valuation currently. Some question mgt�� comment in the PR that the co is positioned for LT double-digit organic revenue and earnings growth. We don�� understand why this matters; it�� not guidance, and the valuation doesn�� reflect anything close to this aspirational goal. We remain focused on the very strong visible 5-yr growth.
Shares of Actavis have gained 8.2% to $268.35, while Allergan has risen 2.1% to $213.51. And even Valeant is having a great day: Its shares are up 5.2% to $143.90.
Best High Dividend Stocks For 2014: Taiwan Semiconductor Manufacturing Co Ltd (TSM)
Taiwan Semiconductor Manufacturing Co., Ltd. is a Taiwan-based company principally engaged in the research, development, manufacture and distribution of integrated circuit (IC) related products. The Company operates its businesses through wafer manufacture, mask production, wafer testing and packaging components. The Company also involves in the provision of production management, customer services and design services. Its products and services are applied in the manufacture of personal computers and peripheral products, information related products, wire and wireless communication systems, automobile and industrial equipment, as well as consumer electronic products, such as digital disk players, digital televisions (TVs), game consoles, digital cameras, among others. Its customers include Altera, AMD, Broadcom, Marvell, NVIDIA, Qualcomm, Analog Devices, Freescale, NXP and Texas Instruments, among others. In July 2010, Taiwan Semiconductor Manufacturing Co. acquired mechanical and engineering equipment from ASML HONG KONG LTD. In September 2010, the Company acquired a set of equipments from ASML HONG KONG LTD. In December 2010, the Company acquired a set of equipment from TOKYO ELECTRON LTD., KLA-TENCOR CORP. and NOVELLUS SYSTEMS INTERNATIONAL,B.V. In January 2011, the Company announced that it had acquired a set of equipment from KLA-TENCOR CORP., a set of equipment and facility, and another set of equipment from VARIAN SEMI. EQUIP. ASSOCIATES GmbH. In March 2011, the Company acquired a set of equipments from Rudolph Technologies, Inc.In March 2011, the Company acquired a set of equipments from Rudolph Technologies, Inc. In May 2011, it acquired a set of equipments form APPLIED MATERIALS SOUTH EAST ASIA PACIFIC LTD., Hamatech APE Gmbh and CO. KG, TOKYO ELECTRON LTD., DAINIPPON SCREEN MFG. CO., LTD., and VARIAN SEMI. EQUIP. ASSOCIATES GMBH.
TSMC's customers include semiconductor companies, ranging from fabless semiconductor and systems companies, such as Advanced Micro Devices, In! c., Altera Corporation, Broadcom Corporation, Marvell Semiconductor Inc., MediaTek Inc., nVidia Corporation and Qualcomm Incorporated, to integrated device manufacturers, such as LSI Corporation, STMicroelectronics and Texas Instruments Inc. Fabless semiconductor and system companies accounted for approximately 80%, and integrated device manufacturers accounted for approximately 20% of its net sales as of December 31, 2009.
The Company manufactures semiconductors using CMOS and BiCMOS processes. The BiCMOS process combines the speed of the bipolar circuitry and the power consumption and density of the CMOS circuitry. It uses the CMOS process to manufacture logic semiconductors, memory semiconductors, including static random access memory (SRAM), flash memory, mixed-signal/ radio frequency (RF) semiconductors, which combine analog and digital circuitry in a single semiconductor, micro-electro-mechanical-system (MEMS), which combines micrometer featured mechanical parts, analog and digital circuitry in a single semiconductor, and embedded memory semiconductors, which combine logic and memory in a single semiconductor. The BiCMOS process is used to make high-end mixed-signal and other types of semiconductors.
Advisors' Opinion:- [By Evan Niu, CFA]
Earlier this month, ARM and Taiwan Semiconductor (NYSE: TSM ) also announced the first "tape-out" of Cortex-A57 processors using TSMC's FinFET process, signaling that the new chips are ready for mass production. ARM inked 22 processor licenses in the first quarter, which includes seven of these newest Cortex-A50 series processors like the Cortex-A57. That brings the company's total Cortex-A50 series licenses to 16.
- [By MONEYMORNING.COM]
The Emerging Markets Index holds Tencent Holdings Ltd., Taiwan Semiconductor Manufacturing (NYSE: TSM), China Mobile Ltd. (NYSE: CHL), and China Construction Bank Corp. (HKG: 0939) �among their top six holdings.
- [By Ashraf Eassa]
We can reasonably assume that Intel spends about $2.5 billion/year on developing its leading-edge manufacturing technologies. To put this into perspective, TSMC (NYSE: TSM ) �-- the world's leading independent semiconductor contract manufacturer -- has spent about $1.64 billion on R&D during the last 12 months, with that run rate more than�double the amount the company spent in 2010. Developing leading-edge manufacturing technology is getting harder and more expensive.
- [By Motley Fool Staff]
Need a reason to invest in stocks? How about the beginning of a new year. To help you find solid stock ideas we asked Fool.com contributors covering technology and consumer goods stocks to talk about top stocks for 2015. Read on to see what they had to say about Qualcomm (NASDAQ: QCOM ) , Facebook (NASDAQ: FB ) , SeaWorld Entertainment (NYSE: SEAS ) , WhiteWave Foods (NYSE: WWAV ) , Google (NASDAQ: GOOG ) (NASDAQ: GOOGL ) , Taiwan Semiconductor (NYSE: TSM ) , and Apple (NASDAQ: AAPL ) .
Best High Dividend Stocks For 2014: International Northair Mines Ltd (INM)
International Northair Mines Ltd is a mineral exploration company engaged in the acquisition, exploration and development of mineral properties throughout North America with a focus in Mexico. In Mexico, exploration is conducted by its wholly owned subsidiary, Grupo Northair de Mexico, S.A. de C.V. (Grupo Northair). Its projects include La Cigarra Project, Sierra Rosario Project, and El Reventon Project. The La Cigarra Project is located near the municipality of Parral, in the State of Chihuahua in north central Mexico. La Cigarra consists of mineral concessions totaling approximately 32,000 hectares. The El Reventon Project is located in the municipality of Otaez, Durango and is approximately 170 kilometers northwest of the capital city of Durango. The El Reventon Project consists of approximately 3,400 hectares. Sierra Rosario silver/gold project is staked by the Company and joint ventured to American Consolidated Minerals Resources Corp., which has a 50% interest in the property. Advisors' Opinion:- [By Alexis Xydias]
The ISEQ Index (ISEQ) in Ireland and the ASE Index in Greece, the first two nations to receive European Union-led bailouts, have soared more than 28 percent this year to lead gains among 18 national benchmarks in western Europe. Dublin-based Independent News & Media Plc (INM) and Athens-based Aegean Airlines SA (AEGN) rose the most, with jumps of more than 180 percent. Germany�� DAX Index (DAX) has advanced 18 percent in 2013, reaching a record.
Best High Dividend Stocks For 2014: Dr. Reddy's Laboratories Ltd(RDY)
Dr. Reddy?s Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec Internatio nal for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddy?s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Advisors' Opinion:- [By Rich Duprey]
Following FDA approval of its abbreviated new drug application, or ANDA,�Dr. Reddy's Laboratories (NYSE: RDY ) announced today that it launched its lamotrigine extended-release tablets, the generic version of GlaxoSmithKline's Lamictal.�
- [By Benjamin Shepherd] We’re now into day 15 of the US government shutdown, as House Republicans stubbornly try to defund Obamacare. No matter what sort of deal is eventually struck, health care costs aren’t likely to come down any time soon. And that’s good news for generic drug makers.
Dr. Reddy’s Laboratories (NYSE: RDY) is one of the biggest players in generic drugs, offering more than 200 off-brand medications in the areas of cardiovascular disease, pain management and oncology, among others. In fact, this India-based company has become one of the largest makers of generics in the world, helping to drive more than 20 percent annual compounded earnings growth at the company over the past decade. - [By Seth Jayson]
Dr. Reddy's Laboratories (NYSE: RDY ) reported earnings on May 14. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q4), Dr. Reddy's Laboratories beat expectations on revenues and beat expectations on earnings per share. - [By Monica Gerson]
Dr. Reddy's Laboratories (NYSE: RDY) is expected to report its Q4 earnings at $0.52 per share.
YuMe (NYSE: YUME) is estimated to post a Q1 loss at $0.15 per share on revenue of $35.36 million.
Best High Dividend Stocks For 2014: Euro Tech Holdings Company Limited(CLWT)
Euro Tech Holdings Company Limited, through its subsidiaries and associated companies, engages in marketing and trading air, water, and waste water related process control, analytical, and testing instruments, as well as disinfection equipment and related automation systems. The company distributes a range of advanced air and water pollution control equipment, chlorination equipment, laboratory instruments, analyzers, test kits, and related supplies; and power generation related equipment, including recorders and power quality analyzers. It also manufactures air and water analytical instruments and testing equipment, as well as undertakes air, water, and waste-water treatment engineering projects. Euro Tech primarily sells its products through its retail shops and representative offices, as well as through independent sub-distributors to commercial customers, governmental agencies, or instrumentalities in Hong Kong and the People?s Republic of China. The company was found ed in 1971 and is headquartered in Hong Kong, Hong Kong.
Advisors' Opinion:- [By James E. Brumley]
If you're like most investors, you've probably never heard of Euro Tech Holdings Co. Ltd. (NASDAQ:CLWT). I have a confession to make - until a few days ago, I hadn't heard of it either. Yet, in just the few short days I've had to get to know CLWT, I've come to the conclusion that if you're the kind of person who would be just as comfortable taking an extra $1000 to the casino as you would be in putting that money into a brokerage account and putting into a crazy stock, then Euro Tech Holdings may be worth a shot to you.
No comments:
Post a Comment